.png){kind=icon}
返回
Current pharmaceutical developments in atopic dermatitis
.png){kind=icon}
PRE
AI
DOI：10.1016/j.coph.2018.12.003.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Atopic dermatitis (AD) is an inflammatory, pruritic, chronic or chronically relapsing skin disease that typically begins in early childhood and is occurring frequently in families with other atopic diseases (bronchial asthma and/or allergic rhino-conjunctivitis). Thanks to immunological and neurobiological research, the era of new treatments is coming as well as it occurred with psoriasis 15 years ago. Many treatments targeting cytokines (IL-4, IL-13, IL-31, TSLP) or neurotransmitters (substance P, opioids) or their respective receptors as well as phosphodiesterase-4 or the Jak/Stat pathways are under development. Antagonists of cytokines and anti-jak have promising effects on pruritus while it is more difficult to discriminate the effects of other drugs from the placebo effect on itch, which is known to be high.
Keyword:
CYCLIC-AMP-PHOSPHODIESTERASE
INTERLEUKIN-31 RECEPTOR
SAFETY
INFLAMMATION
EXPRESSION
INHIBITOR
DUPILUMAB
EFFICACY
PLACEBO
CONTRIBUTES
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
4.2
论文数:
2.5K
被引数:
6.7K
机构
引用论文
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialdupilumab联合外用皮质类固醇治疗中至重度特应性皮炎的长期治疗 (LIBERTY AD CHRONOS): 一项为期1年的随机双盲安慰剂对照3期试验.png)
LANCET
LANCETIF88.5
PREAI
分享收藏Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
OAAI
OAAI分享收藏
查看更多内容